Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus

• DOI: 10.1007/s00277-021-04746-y
• Publication Date: 2022-01-07T13:02:53Z
• Authors: Larissa Henze; Christoph Buhl; Michael Sandherr; Oliver A. Cornely; Werner J. Heinz; Yascha Khodamoradi; Til Ramon Kiderlen; Philipp Koehler; Alrun Seidler; Rosanne Sprute; Martin Schmidt-Hi...; Marie von Lilienf...
• Keywords: Herpesvirus 3, Human; Herpes Genitalis; Herpesvirus 2, Human; Vaccination; 610; Acyclovir; Disease Management; Herpes Simplex; Herpesvirus 1, Human; ddc:no; Antiviral Agents; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Germany; Hematologic Neoplasms; Neoplasms; Varicella Zoster Virus Infection; Humans; Original Article; Virus Activation

Abstract Clinical reactivations of herpes simplex virus or varicella zoster virus occur frequently among patients with malignancies and manifest particularly as herpes simplex stomatitis in patients with acute leukaemia treated with intensive chemotherapy and as herpes zoster in patients with lymphoma or multiple myeloma. In recent years, knowledge on reactivation rates and clinical manifestations has increased for conventional chemotherapeutics as well as for many new antineoplastic agents. This guideline summarizes current evidence on herpesvirus reactivation in patients with solid tumours and hematological malignancies not undergoing allogeneic or autologous hematopoietic stem cell transplantation or other cellular therapy including diagnostic, prophylactic, and therapeutic aspects. Particularly, strategies of risk adapted pharmacological prophylaxis and vaccination are outlined for different patient groups. This guideline updates the guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) from 2015 “Antiviral prophylaxis in patients with solid tumours and haematological malignancies” focusing on herpes simplex virus and varicella zoster virus.